Biotechnology

The PolG Foundation awards over $3.5M in academic grants to pioneer POLG research

NEW YORK and PARIS, Nov. 15, 2023 /PRNewswire/ --The PolG Foundation is a nascent foundation established in 2022 by a PolG family, with the mission to support and accelerate research to find effective treatments and a cure for PolG mitochondrial disorders.  To view the Multimedia News Release, p...

2023-11-15 20:42 1599

Henlius Reported Financial Results for the First Three Quarters of 2023: Total Revenue Exceeded RMB3.9 billion, Profitability Further Improved

SHANGHAI, Nov. 15, 2023 /PRNewswire/ -- Henlius(2696.HK)announced its financial results and business update for the first three quarters of 2023. As of September 30, 2023, Henlius generated a total revenue of RMB3.9278 billion, rising by 84.0% YoY, and a profit totaledRMB407.8 million, attributed ...

2023-11-15 20:16 2510

RemeGen to Present Telitacicept Phase III Clinical Trial Results for Rheumatoid Arthritis Patients in a Late-Breaking Abstract Oral Presentation Session at the American College of Rheumatology

YANTAI, China, Nov. 15, 2023 /PRNewswire/ -- RemeGen Co., Ltd.  ("RemeGen" or "the Company") (HKG: 9995, SHA: 688331), a commercial-stage biotechnology company, is invited to present telitacicept Phase III Clinical Trial Results for Rheumatoid Arthritis Patients in a Lat...

2023-11-15 16:35 1526

Riding the tide, realize the future: The BD paths for Chinese Biotech

WUXI, China, Nov. 14, 2023 /PRNewswire/ -- 2023 BIO-Europe just closed last week. In line with previous conferences, this BD carnival attracted more than 2,000 companies, 5,000 attendees from close to 60 countries all over the world. Recently, we interviewed a global BD expert, Dr. Kaan Certel.  ...

2023-11-15 10:42 1034

2023 World Laureates Association Prize winners awarded in Shanghai

SHANGHAI, Nov. 14, 2023 /PRNewswire/ -- The five winners of the 2023 World Laureates Association Prize (WLA Prize) received their awards for their ground-breaking achievements in computer science or mathematics and life science or medicine onNov. 6 at the opening ceremony of the 6th WLA Forum hel...

2023-11-15 09:54 3600

BioDuro-Sundia Radioisotope Laboratory Technology Upgrades Accelerate Innovation

SHANGHAI, Nov. 15, 2023 /PRNewswire/ -- Radioisotope assays a microanalytical method that uses radionuclides as tracers to label research objects. Compared with conventional biological sample detection techniques, Radioisotope assay has distinct advantages such as high specificity, high sensitivi...

2023-11-15 09:00 1341

EDAN's Focus on Medical Technology Advancement Shines at MEDICA 2023

DUSSELDORF, Germany, Nov. 14, 2023 /PRNewswire/ -- Edan Instruments Inc. (300206.SZ), a leading global provider of medical and healthcare solutions, showcased its innovative range of new products at MEDICA 2023 inGermany. This grand event, anticipated to draw over 81,000 v...

2023-11-14 22:31 1338

Noble Capital Markets Initiates Coverage on YS Biopharma With Outperform Rating and US$5.25 Price Target

GAITHERSBURG, Md., Nov. 14, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious disea...

2023-11-14 21:30 1161

CytoMed Therapeutics to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

SINGAPORE, Nov. 14, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited  (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore -based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based allogeneic immunotherap...

2023-11-14 20:47 989

HaemaLogiX Announces Appointment of Damian Clarke-Bruce as Managing Director and CEO

SYDNEY, Nov. 13, 2023 /PRNewswire/ -- HaemaLogiX Ltd, a clinical stage Australian biotech, is pleased to announce the appointment ofDamian Clarke-Bruce as Managing Director and CEO, effective13 November 2023. Outgoing CEO Bryce Carmine will remain active in the company, retaining his role as Cha...

2023-11-14 08:27 1062

Brii Bio Presents New Data Highlighting Progress Towards Achieving HBV Functional Cure at AASLD's The Liver Meeting® 2023

Direct evidence that BRII-179-induced functional antibody responses can contribute to increased and sustained HBsAg loss rate New insight in utilizing BRII-179 to enriching patients with intrinsic humoral immune responses for higher HBsAg loss or HBV functional cure rates New data support ...

2023-11-14 06:40 1257

Brii Bio Presents New Data Highlighting Progress Towards Achieving HBV Functional Cure at AASLD's The Liver Meeting® 2023

Direct evidence that BRII-179-induced functional antibody responses can contribute to increased and sustained HBsAg loss rate New insight in utilizing BRII-179 to enriching patients with intrinsic humoral immune responses for higher HBsAg loss or HBV functional cure rates New data support ...

2023-11-14 06:40 1424

SCG Cell Therapy Announces Late-Breaking Clinical Data at AASLD Showing SCG101 Improved Tumor Reponses and Achieved Sustained Antiviral Activates in Patients with Advanced HBV-related Hepatocellular Carcinoma

SINGAPORE, Nov. 14, 2023 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company developing novel immunotherapies for infectious diseases and their associated cancers, today announced late-breaking clinical data from its first-in-class autologous hepatitis B virus ...

2023-11-14 02:00 2346

OliPass Discloses Painful but Hilarious Clinical Findings from a Phase 2a Trial in OA Patients with Nav1.7 Selective Inhibitor OLP-1002

SEOUL, South Korea, Nov. 13, 2023 /PRNewswire/ -- OliPass Corporation, an RNA therapeutics platform company, disclosed uncanny clinical findings from a multi-center Phase 2a trial with Nav1.7 selective OLP-1002 in osteoarthritis (OA) patients with moderate to severe pain inAustralia with Novotech...

2023-11-13 22:00 1132

Ipsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC)

Bylvay (odevixibat) is the first and only oral treatment available in Canada for the treatment of pruritus due to this rare genetic condition ZUG, Switzerland and PARIS, Nov. 13, 2023 /PRNewswire/ -- Today, Ipsen (Euronext: IPN) (ADR: IPSEY), a global biopharmaceutical c...

2023-11-13 20:20 1116

Telix and Mauna Kea Technologies to Expand Collaboration in Urologic Oncology Surgery

MELBOURNE, Australia and PARIS, Nov. 13, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) andParis-based Mauna Kea Technologies (Euronext Growth: ALMKT,Mauna Kea), today announce an expansion of the IRiS (Imaging and Robotics in Surgery) Alliance[1] through a stra...

2023-11-13 16:27 1241

Nona Biosciences Announces Strategic Collaboration with GeneQuantum Healthcare to Empower Early Discovery of Next-Generation Bioconjugates

CAMBRIDGE, Mass., Nov. 13, 2023 /PRNewswire/ -- Nona Biosciences, a global pioneer of technology innovation and antibody discovery and development solutions, today announced that it has entered into a strategic collaboration with GeneQuantum Healthcare to advance the early discovery of next-gener...

2023-11-13 16:04 1155

Ascletis Announces Poster Presentations at AASLD Annual Meeting 2023 Including a Late-Breaking Abstract of Interim Results from Phase IIb Expansion Cohort of ASC22 for Functional Cure of CHB

HANGZHOU and SHAOXING, China, Nov. 13, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces late-breaking abstract poster presentation of interim results from Phase IIb expansion cohort of ASC22 (Envafolimab) for functional cure of chronic hepatitis B (CHB), and abst...

2023-11-13 08:10 1901

First Patient Dosed in Phase III ProstACT GLOBAL Study of Antibody-based Prostate Cancer Therapy Candidate, TLX591

MELBOURNE, Australia, Nov. 13, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in the Company's Phase III ProstACT GLOBAL study of its investigational prostate-specific membrane antigen (PSMA) targeting radio...

2023-11-13 07:38 1221

Fapon Inaugurates State-of-the-Art R&D Center in Lexington, MA

LEXINGTON, Mass., Nov. 11, 2023 /PRNewswire/ -- Fapon, a global leading life sciences organization, is thrilled to announce the grand opening of its US-based Research and Development (R&D) Center, strategically located in Lexington, Massachusetts. This Center represents Fapon's unwavering commitme...

2023-11-11 20:36 2687
1 ... 29303132333435 ... 280